DUCHENNE MUSKÜLER DİSTROFİ TAŞIYICI KADINLARDA GÖRÜLEN SEMPTOMLAR: GELENEKSEL DERLEME

Öz

Duchenne Musküler Distrofi (DMD); nöromüsküler hastalıklar arasında en yaygın görülen, distrofin proteini eksikliğinden kaynaklanan X’e bağlı resesif geçişli genetik hastalıktır. Hastalıkta iskelet kası ve kardiyopulmoner tutulumun yanı sıra kognitif tutulum da eşlik edebilir. Etkilenen erkek bireylerin üçte biri mutasyon sonucu oluşurken, üçte ikisi ise annelerinden genetik geçiş ile olduğu düşünülmektedir. Taşıyıcı kadınlar, Becker Musküler Distrofi benzeri hafif seyirli bulgulardan DMD’li bireylerde görülen şiddetli semptomlara varan farklı klinik tabloya sahip olabilirler. İlk belirti gösterme yaşları 2 ila 47 yaş arasında değişmektedir. Taşıyıcı kadınlarda da etkilenmiş erkek bireyde görülen kas gücü ve işlevsellik kaybı, kramp, ağrı, kardiyomiyopati, bilişsel disfonksiyon, hafıza ve dikkat bozukluğu gibi semptomlar görülebilmektedir. Hamilelik, doğum, anestezi gibi majör olaylar ile de semptomların şiddeti artmaktadır. DMD kronik ve progresif bir hastalıktır. Bu hastalığa sahip bireylerin bakımını genellikle anneleri üstlenmektedir. DMD’li bireyin bakımından sorumlu taşıyıcı bireyin üzerindeki bakım yükü; hastalığın ilerlemesi, fiziksel ve fonksiyonel kayıpların artmasıyla daha da artar. Bu durum da taşıyıcı birey üzerindeki fiziksel, duygusal, psikolojik vb. yükü artırarak taşıyıcı semptomlarının şiddetinin artmasına sebep olur. Bu yüzden DMD’li birey ile kalıtımsal bağı olan kişiler genetik danışmanlık almaya yönlendirilmeli ve DMD’li bireylerin tedavisi planlanırken bireysel tedavi programına ek olarak genetik danışmanlık sonucunda taşıyıcı olan bireylerin de tedavi programına dahil edildiği aile temelli tedavi yaklaşımı uygulanmalıdır.

Anahtar Kelimeler

• Duchenne müsküler distrofi
• distrofin
• kadın
• bakıcı yükü

SYMPTOMS OF DUCHENNE MUSCULAR DYSTROPHY IN CARRIER WOMEN: A TRADITIONAL REVIEW

Öz

Duchenne Muscular Dystrophy (DMD); The most common neuromuscular disease is an X-linked recessive genetic disease caused by a deficiency of the dystrophin protein. In addition to skeletal muscle and cardiopulmonary involvement, cognitive involvement may accompany the disease. One-third of affected males are caused by mutation, while two-thirds are thought to be inherited from their mothers. Carrier women may have a different clinical picture, ranging from mild signs like Becker Muscular Dystrophy to severe symptoms seen in individuals with DMD. The age at first symptom onset ranges from 2 to 47 years. Symptoms such as loss of muscle strength and functionality, cramps, pain, cardiomyopathy, cognitive dysfunction, memory and attention disorders can be seen in carrier women as well as in affected males. The severity of symptoms increases with major events such as pregnancy, childbirth and anesthesia. DMD is a chronic and progressive disease. The care of individuals with this disease is usually undertaken by their mothers. The burden of care on the carrier responsible for the care of the individual with DMD; The progression of the disease increases with the increase of physical and functional losses. In this case, the physical, emotional, psychological etc. on the carrier individual. Increases the burden, causing an increase in the severity of carrier symptoms. Therefore, people with hereditary ties to the individual with DMD should be directed to receive genetic counseling, and when planning the treatment of individuals with DMD, a family-based treatment approach should be applied in which individuals who are carriers as a result of genetic counseling are included in the treatment program in addition to the individual treatment program.

Anahtar Kelimeler

• Duchenne muscular dystrophy
• dystrophin
• female
• caregiver burden

Kaynakça

1. KAYNAKLAR 1. Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D. et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. The Lancet Neurol. 2018; 17(3):251-267.
2. 2. Crisafulli S, Sultana J, Fontana A, Salvo F, Messina S, Trifirò G. Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet J. Rare Dis. 2020; 15: p. 1-20.
3. 3. Fox H, Millington L, Mahabeer I, Van Ruiten H. Duchenne muscular dystroph. BMJ. 2020; 368.3.
4. 4. Suthar R, Sankhyan N. Duchenne muscular dystrophy: A practice update. IJP. 2018; 85(4):276-281.
5. 5. Grimm T, Kress W, Meng G, Müller CR. Risk assessment and genetic counseling in families with Duchenne muscular dystrophy. Acta Myol. 2012; 31(3): p. 179.
6. 6. Soltanzadeh P, Friez MJ, Dunn D, von Niederhausern A, Gurvich OL, Swoboda KJ et al. Clinical and genetic characterization of manifesting carriers of DMD mutations. Neuromuscul Disord. 2010; 20(8): 499-504.
7. 7. Seemann N, Selby K, McAdam L, Biggar D, Kolski H, Goobie S. Symptomatic dystrophinopathies in female children. Neuromuscul. Disord. 2011; 21(3):172-177.
8. 8. Giliberto F, Radic CP, Luce L, Ferreiro V, de Brasi C, Szijan I. Symptomatic female carriers of Duchenne muscular dystrophy (DMD): genetic and clinical characterization. J. Neurol. Sci. 2014; 336(1-2):36-41. 9. Amos-Landgraf JM, Cottle A, Plenge RM, Friez M, Schwartz EC, Longshore J. et al. X Chromosome–inactivation patterns of 1,005 phenotypically unaffected females. Am. J. Hum. Genet. 2006; 79(3):493-499.

9. 10. Papa R, Madia F, Bartolomeo D, Trucco F, Pedemonte M, Traverso M. et al. Genetic and early clinical manifestations of females heterozygous for Duchenne/Becker muscular dystrophy. Pediatr. Neurol. 2016; 55:58-63
10. 11. Lim KRQ, Sheri N, Nguyen O, Toshifumi Yokota T. Cardiac involvement in dystrophin-deficient females: Current understanding and implications for the treatment of dystrophinopathies. Genes. 2020; 11(7):765.
11. 12. Ahn AH, Kunkel LM. The structural and functional diversity of dystrophin. Nat. Genet. 1993; 3(4):283-291.
12. 13. Takeshima Y, Yagi M, Okizuka Y, Awano H, Zhang Z, Yumiko Yamauchi Y. et al. Mutation spectrum of the dystrophin gene in 442 Duchenne/Becker muscular dystrophy cases from one Japanese referral center. J. Hum. Genet. 2010; 55(6):379-388
13. 14. Lee T, Takeshima Y, Kusunoki N, Awano H, Yagi M, Matsuo M. et al. Differences in carrier frequency between mothers of Duchenne and Becker muscular dystrophy patients. J. Hum. Genet. 2014; 59(1):46-50.
14. 15. Toksoy G, Durmus H, Aghayeva A, Bagirovaa G, Rustemoglua BS, Basarana S. et al. Mutation spectrum of 260 dystrophinopathy patients from Turkey and important highlights for genetic counseling. Neuromuscul. Disord. 2019; 29(8):601-613.
15. 16. Silva THD , Anequini İP, Favero FM, Voos MC, Oliveria ASB, Telles JAR et al. Functional performance and muscular strength in symptomatic female carriers of Duchenne muscular dystrophy. Arq. Neuro-psiquiatr. 2020; 78:143-148.
16. 17. Cotta A, Paim JF, Carvalho E, Navarro MM, Valicek J, da-Cunha-Junior AL. et al. Phenotypic variability of dystrophinopathy symptomatic female carriers. Can J. Neurol. Sci. 2017; 44(3):304-310.
17. 18. Forbes SC, Lott DJ, Finkel RS, Senesac C, Byrne BJ, Sweeney HL et al. MRI/MRS evaluation of a female carrier of Duchenne muscular dystrophy. Neuromuscul. Disord. 2012; 22:111-S121.
18. 19. Preuße C, von Moers A, Kölbel H, Pehl D, Goebel HH, Scharac U. et al. Inflammation-induced fibrosis in skeletal muscle of female carriers of Duchenne muscular dystrophy. Neuromuscul. Disord. 2019; 29(7):487-496.
19. 20. Friedrich O, von Wegner F, Chamberlain JS, Fink RHA, Rohrbach P. L-type Ca2+ channel function is linked to dystrophin expression in mammalian muscle. PLoS One, 2008; 3(3):1762
20. 21. Ishizaki M, Kobayashi M, Adachi K, Matsumura T, Kimura E. Female dystrophinopathy: Review of current literature. Neuromuscul. Disord., 2018; 28(7):572-581.
21. 22. Eekhoff L, Edwards J, Martin A, Prijoles EJ. Assessing the barriers to cardiac care in carriers of Duchenne and Becker muscular dystrophy. J. Genet. Couns. 2019; 28(5):993-1002.
22. 23. Blake DJ, Kröger S. The neurobiology of Duchenne muscular dystrophy: learning lessons from muscle? Trends Neurosci. 2000; 23(3):92-99.
23. 24. Landfeldt E, Thompson R, Sejersen T, McMillan HJ, Janbernd Kirschner J, Hanns Lochmüller H. Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis. Eur. J. Epidemiol. 2020; 35(7): 643-653.
24. 25. Landfeldt E, Lindgren P, Bell CF, Guglieri M, Volker Straub V, Lochmuller H. et al. Quantifying the burden of caregiving in Duchenne muscular dystrophy. J. Neurol. 2016; 263(5):906-915.
25. 26. Gieron-Korthals M, Fernandez R. New Developments in Diagnosis, Treatment, and Management of Duchenne Muscular Dystrophy. Adv. Pediart. 2020; 67:183-196.
26. 27. Gaınes RF, Pueschel SM, Sassaman EA, Drıscoll JL. Effect of exercise on serum creatine kinase in carriers of Duchenne muscular dystrophy. J. Med. Genet. 1982. 19(1): p. 4-7.
27. 28. Petrof BJ. The molecular basis of activity-induced muscle injury in Duchenne muscular dystrophy. Mol. Cell. Biochem. 1998; 179(1):111-124.
28. 29. Cho YN, Choi YC. Female Carriers of Duchenne Muscular Dystrophy. J Genet Med 2013;10(2):94-98
29. 30. Sakthivel Murugan SM, Arthi C, Thilothammal N, Lakshmi BR. Carrier detection in Duchenne muscular dystrophy using molecular methods. Indian J Med Res. 2013 Jun; 137(6): 1102–1110
30. 31. Lewis C, Skirton H, Jones R. Can we make assumptions about the psychosocial impact of living as a carrier, based on studies assessing the effects of carrier testing? J. Genet. Couns. 2011; 20(1):80-97.
31. 32. Botkin JR, Belmont JW, Berg JS, Berkman BE, Bombard Y, Holm IA et al. Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. Am. J. Hum. Genet. 2015; 97(1):6-21.
32. 33. Fraser HG, Redmond RZ, Scotcher DF. Experiences of women who have had carrier testing for Duchenne muscular dystrophy and Becker muscular dystrophy during adolescence. J. Genet. Couns. 2018; 27(6):1349-1359.
33. 34. Borry P, Fryns JP, Schotsmans P, Kris Dierickx K. Carrier testing in minors: a systematic review of guidelines and position papers. Eur. J. Hum. Genet. 2006; 14(2):133-138.
34. 35. The British Society for Human Genetics. Report on the Genetic Testing of Children 2010. Available at: https://www.southampton.ac.uk/~assets/doc/report%20on%20genetic%20testing%20of%20children.pdf
35. 36. Huijben J, Merel Jansen M, Ginjaar LB, Lammens M, van Putten M, van Alfen N. et al. What can we learn from assisted bicycle training in a girl with dystrophinopathy? A case study. J. Child Neurol. 2015; 30(5): 659-663.
36. 37. Vang P, Baumann, CW, Barok R, Larson AA, Dougherty BJ, Lowe DA. Impact of estrogen deficiency on diaphragm and leg muscle contractile function in female mdx mice. PLoS One. 2021;16(3), e0249472.
37. 38. Demirci H, Durmus H, Toksoy G, Uslu A, Parman Y, Hasmet Hanagasi H. Cognition of the mothers of patients with Duchenne muscular dystrophy. Muscle Nerve. 2020; 62(6):710-716.
38. 39. Gocheva V, Simone Schmidt S, Orsini AL, Hafner P, Schaedelin S, Weber P. et al. Psychosocial adjustment and parental stress in Duchenne Muscular Dystrophy. Eur. J. Pediatr. Neurol. 2019. 23(6): p. 832-841.
39. 40. Jackson JL, Korth CX, Leslie CE, Cotto J, Mah ML, Hor K. et al. Health-Related Quality of Life and Emotional Distress Among Mothers of Sons With Muscular Dystrophy as Compared to Sex-and Age Group–Matched Controls. J. Child Neurol. 2021. 36(3): p. 177-185.